Cilostazol: A Potential Therapeutic Option to Prevent In-Stent Restenosis  by Dihu, Jamil B. et al.
RR
2035JACC Vol. 57, No. 20, 2011 Correspondence
May 17, 2011:2034–6the case report data that have been used to argue in favor of
exercise restriction in patients with aortic stenosis. As we contem-
plate cost-effective means of compiling a much larger dataset that
will improve the confidence intervals we can apply to both the risks
and benefits of exercise participation in this population, practicing
clinicians will need to continue to make this judgment on a daily
basis. Our data undoubtedly do not absolutely exclude the possi-
bility of an increased risk of exercise-associated sudden death in
subjects with aortic stenosis, but they certainly provide no evidence
to support it. This, coupled with the clear evidence of benefit from
regular exercise participation, lead us to the opinion that current
evidence does not support continuation of these restrictions.
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Cilostazol: A Potential
Therapeutic Option to
Prevent In-Stent Restenosis
It was of great interest and utility to read the paper by Dangas
et al. (1) pertaining to in-stent restenosis (ISR) in drug-eluting
stents (DES). The authors reviewed systematically the pathophys-
iological, mechanical, and technical mechanisms and treatment
options of ISR in DES. The proposed treatment algorithm is an
important clinical tool for a challenging problem without a proven
treatment regimen. We would like to present another possible
treatment option available for ISR. We believe that the plateletphosphodiesterase III (PDE III) inhibitor cilostazol may poten-
tially have a beneficial role in the treatment of ISR in DES.
Cilostazol is approved and widely used for the treatment of
intermittent claudication. It has properties that inhibit several
biological mechanisms, such as smooth muscle proliferation, which
may lead to ISR (2). PDE III inhibitors reduce P-selectin
expression on platelets and Mac-1 on the surface of neutrophils.
Mac-1 has been shown to be a key protein involved in neointimal
hyperplasia and in the pathophysiology of ISR, and rises during
the 48 h after PCI (3).
In previous clinical trials, it has been shown that PDE III
inhibitors reduce the rate of ISR. In the CREST (Cilostazol for
REStenosis Trial), cilostazol was shown to significantly reduce
neointimal hyperplasia and the rate of restenosis in a population of
patients undergoing bare-metal stent implantation (4). Cilostazol
has also been shown to reduce the rate of ISR in patients treated
with DES. In a group of diabetic patients treated with DES,
cilostazol was shown to reduce the rate of angiographic restenosis
and target lesion revascularization without an increase in severe
adverse effects (5). In 1 trial, cilostazol therapy showed a 40.2%
relative risk reduction in ISR in patients with DES of 32 mm
(6). Patients in the trial were also noted to have significantly lower
rates of in-segment and in-stent late loss, as well as a reduced rate
of target vessel revascularization. A recent meta-analysis of the
effects of cilostazol in patients treated with both bare-metal stents
and DES found that in 2,809 patients pooled from 10 different
randomized trials, cilostazol reduced late loss by a mean difference
of 0.15 mm. Binary angiographic restenosis was also significantly
lower in patients treated with cilostazol, regardless of the type of
stent used (7).
The use of cilostazol to prevent ISR has shown promise in the
limited clinical trials available. These trials are not without
limitations. Adding cilostazol use would subject patients to an-
other antiplatelet agent that could potentially lead to an increased
bleeding risk. It should also be noted that the clinical trials
mentioned have a rather limited follow-up period, and the patient
population in those studies is not ethnically diverse. Cilostazol was
also used in the study population as an agent for primary
prophylaxis and not as a secondary therapy. Though little definitive
evidence is available, we believe that the data for the use of
cilostazol to prevent ISR are promising, warrant further investiga-
tion, and may provide clinicians with another therapeutic option.
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